| Title |
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
|
|---|---|
| Published in |
Breast Cancer Research, December 2019
|
| DOI | 10.1186/s13058-019-1196-y |
| Pubmed ID | |
| Authors |
Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M. Orcutt, Marina E. Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S. Kim, Huichen Feng, Corey Lipchik, Peter C. Lucas, Ashok Srinivasan, Ying Wang, Nan Song, Patrick G. Gavin, April D. Balousek, Soonmyung Paik, Carmen J. Allegra, Norman Wolmark, Katherine L. Pogue-Geile |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 48 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 10% |
| Researcher | 5 | 10% |
| Student > Bachelor | 5 | 10% |
| Student > Postgraduate | 4 | 8% |
| Student > Doctoral Student | 3 | 6% |
| Other | 10 | 21% |
| Unknown | 16 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 29% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Nursing and Health Professions | 2 | 4% |
| Agricultural and Biological Sciences | 2 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Other | 5 | 10% |
| Unknown | 20 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 December 2019.
All research outputs
#17,295,853
of 25,387,668 outputs
Outputs from Breast Cancer Research
#1,536
of 2,054 outputs
Outputs of similar age
#296,869
of 473,301 outputs
Outputs of similar age from Breast Cancer Research
#21
of 30 outputs
Altmetric has tracked 25,387,668 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,054 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 473,301 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.